CN100509055C - 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 - Google Patents

使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 Download PDF

Info

Publication number
CN100509055C
CN100509055C CNB028185722A CN02818572A CN100509055C CN 100509055 C CN100509055 C CN 100509055C CN B028185722 A CNB028185722 A CN B028185722A CN 02818572 A CN02818572 A CN 02818572A CN 100509055 C CN100509055 C CN 100509055C
Authority
CN
China
Prior art keywords
ulcer
gly
application
group
peptide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028185722A
Other languages
English (en)
Chinese (zh)
Other versions
CN1556711A (zh
Inventor
达芮尔·H·卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capstone Holding Corp
Original Assignee
Osorogis Ltd
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osorogis Ltd, University of Texas System filed Critical Osorogis Ltd
Publication of CN1556711A publication Critical patent/CN1556711A/zh
Application granted granted Critical
Publication of CN100509055C publication Critical patent/CN100509055C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB028185722A 2001-07-27 2002-01-16 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 Expired - Fee Related CN100509055C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30819801P 2001-07-27 2001-07-27
US60/308,198 2001-07-27

Publications (2)

Publication Number Publication Date
CN1556711A CN1556711A (zh) 2004-12-22
CN100509055C true CN100509055C (zh) 2009-07-08

Family

ID=23192964

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028185722A Expired - Fee Related CN100509055C (zh) 2001-07-27 2002-01-16 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡

Country Status (11)

Country Link
US (3) US7049294B2 (enExample)
EP (1) EP1414487B1 (enExample)
JP (1) JP4192093B2 (enExample)
CN (1) CN100509055C (enExample)
AT (1) ATE328606T1 (enExample)
AU (1) AU2002236768B2 (enExample)
CA (1) CA2455756C (enExample)
DE (1) DE60212143T2 (enExample)
DK (1) DK1414487T3 (enExample)
ES (1) ES2271216T3 (enExample)
WO (1) WO2003013569A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100509055C (zh) * 2001-07-27 2009-07-08 奥索洛吉艾斯有限公司 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
EP1539800B1 (en) * 2002-07-02 2007-05-23 Orthologic Corp. Thrombin peptide derivative dimers
AU2003256343B2 (en) * 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives
DE602004005564T2 (de) 2003-12-31 2007-12-13 Orthologic Corp., Tempe Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
WO2007035406A1 (en) * 2005-09-16 2007-03-29 Orthologic Corp. Antibodies to complementary peptides of thrombin or portions thereof
WO2008124172A1 (en) * 2007-04-10 2008-10-16 The Board Of Regents, The University Of Texas System Combination therapy for chronic dermal ulcers
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
EP2268304A2 (en) * 2008-03-26 2011-01-05 Orthologic Corp. Methods for treating acute myocardial infarction
AU2009229395A1 (en) * 2008-03-26 2009-10-01 The Board Of Regents, The University Of Texas System Method of treating degenerative diseases
US20110117075A1 (en) * 2008-03-26 2011-05-19 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
GB0916576D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
EP2538874A4 (en) * 2010-02-24 2017-06-21 Syneron Medical Ltd. A body contouring apparatus
US8806615B2 (en) 2010-11-04 2014-08-12 Mcafee, Inc. System and method for protecting specified data combinations
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
CZ308845B6 (cs) * 2019-01-21 2021-07-07 Globetech Innovation S.R.O Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049309A2 (en) * 1999-12-29 2001-07-12 Pfizer Limited Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue
WO2002044413A2 (en) * 2000-12-01 2002-06-06 Response Genetics, Inc. Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
AU5638096A (en) 1995-06-07 1996-12-30 Clarion Pharmaceuticals, Inc. Non-biological patch for hemostasis
CN100509055C (zh) * 2001-07-27 2009-07-08 奥索洛吉艾斯有限公司 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049309A2 (en) * 1999-12-29 2001-07-12 Pfizer Limited Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue
WO2002044413A2 (en) * 2000-12-01 2002-06-06 Response Genetics, Inc. Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
acceleration of full-thickness wound healing in normalratsbythe synthetic thrombin peptide,TP508. Stiernberg J 等.wound repair and regeneration,Vol.8 No.3. 2000 *

Also Published As

Publication number Publication date
WO2003013569A3 (en) 2003-12-11
DE60212143D1 (de) 2006-07-20
ES2271216T3 (es) 2007-04-16
AU2002236768B2 (en) 2006-06-08
EP1414487A2 (en) 2004-05-06
JP2004538320A (ja) 2004-12-24
WO2003013569A2 (en) 2003-02-20
HK1065719A1 (en) 2005-03-24
US7833982B2 (en) 2010-11-16
US7049294B2 (en) 2006-05-23
CN1556711A (zh) 2004-12-22
US20060241049A1 (en) 2006-10-26
CA2455756A1 (en) 2003-02-20
DK1414487T3 (da) 2006-10-09
DE60212143T2 (de) 2007-04-12
US7378500B2 (en) 2008-05-27
ATE328606T1 (de) 2006-06-15
EP1414487B1 (en) 2006-06-07
US20090029923A1 (en) 2009-01-29
CA2455756C (en) 2013-04-02
JP4192093B2 (ja) 2008-12-03
US20040209819A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
CN100509055C (zh) 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
US20220306704A1 (en) Neurotoxins for use in inhibiting cgrp
JP7109097B2 (ja) 角膜創傷治癒および眼表面疾患のためのヒスタチン
JP2022123073A (ja) Ｅｆｐの治療または低減方法
KR101514414B1 (ko) 당뇨병성 족부 궤양의 치료방법
AU2002236768A1 (en) Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
CN108463470B (zh) 胶原蛋白7的组合物及其使用方法
Peng et al. Proteomics identification of targets for intervention in pressure ulcers
CN106488773A (zh) Apc类似物用于创伤愈合的用途
JP2005508875A5 (enExample)
JP2016502558A (ja) 眼疾患の治療における使用のためのタンパク質ｓｌｕｒｐ−１
Rao et al. Recombinant human epidermal growth factor in healing of pressure ulcers
CN117085115A (zh) 胱抑素a在制备促进皮肤创面愈合的药物中的用途
RU2149644C1 (ru) Способ лечения заболеваний, сопровождающихся образованием гноя и/или некротических тканей
HK1065719B (en) Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
CN112190687A (zh) 一种用于减少皮肤创伤瘢痕的药物及其应用
JPH0429936A (ja) 悪性脳腫瘍治療用医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: OSOLUGIAIS CO., LTD.

Free format text: FORMER OWNER: THE BOARD OF REGENTS, THE UNIV. OF TEXAS SYSTEM

Effective date: 20051223

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20051223

Address after: Arizona, USA

Applicant after: Orthologic Corp.

Address before: American Texas

Applicant before: Board of Regents of the Univ. of Texas System

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090708

Termination date: 20160116

EXPY Termination of patent right or utility model